highperformr logo

Aeglea BioTherapeutics's Overview

Total employees13
HeadquartersAustin
Founded2013

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company that was focused on developing enzyme-based therapeutics for patients with rare metabolic diseases. Their lead product candidate, pegzilarginase, was developed for the treatment of Arginase 1 Deficiency. Following disappointing Phase 3 trial results for pegzilarginase in 2023, the company underwent significant restructuring, reduced its workforce, and is exploring strategic alternatives. They also have other preclinical programs targeting metabolic diseases.

Where is Aeglea BioTherapeutics's Headquarters?

HQ Function

The headquarters serves as the central hub for corporate operations, research and development leadership, clinical trial management, and strategic decision-making.

Notable Features:

Located in a modern office building in downtown Austin, providing access to a vibrant business environment and talent pool.

Work Culture:

Following recent restructuring, the work culture is likely focused on resilience, strategic re-evaluation, and dedication to advancing its remaining scientific programs. Emphasis would be on lean operations and collaborative problem-solving.

HQ Significance:

The Austin location places Aeglea within a dynamic biotech ecosystem, offering opportunities for collaboration and access to skilled professionals. However, its significance is currently tied to its ability to navigate its strategic review.

Values Reflected in HQ: The headquarters, even in a period of transition, would aim to reflect values such as scientific rigor, innovation, and a commitment to addressing unmet medical needs in rare diseases.

Location:

Aeglea BioTherapeutics is primarily based in the United States. While their clinical trials may have involved international sites, their core operations and physical offices are U.S.-centric. Global functions would have primarily related to clinical trial coordination and potentially future commercialization efforts, which are now under review.

Street Address:

221 W 6th St, Suite 1450

City:

Austin

State/Province:

Texas

Country:

USA

Aeglea BioTherapeutics's Global Presence

Buying Intent Signals for Aeglea BioTherapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Aeglea BioTherapeutics

As of April 2025, Aeglea BioTherapeutics' leadership includes:

Jeffrey Goldberg - President, Chief Executive Officer and Director
Cortney Caudill - Chief Product Officer
Linda Neuman - General Counsel and Corporate Secretary

Investors of Aeglea BioTherapeutics

Aeglea BioTherapeutics has been backed by several prominent investors over the years, including:

Lilly Asia Ventures
Novartis Venture Fund
Jennison Associates
RA Capital Management
OrbiMed
Rock Springs Capital
Ally Bridge Group
UT Horizon Fund

Executive New Hires/Exits in the Last 12 Months

Hire1
Exits2

Aeglea BioTherapeutics has experienced significant leadership changes over the past 12-18 months, including a new CEO appointment and departures corresponding with the company's restructuring efforts after its lead drug candidate's trial results.

Departures

Anthony G. Quinn, M.B., Ch.B., Ph.D., Anthony Quinn resigned as President and CEO.
Jonathan P. Graham, Jonathan P. Graham departed as CFO during company restructuring.

New Appointments:

Jeffrey Goldberg, Jeffrey Goldberg appointed as new President and CEO.

Technology (Tech Stack) used by Aeglea BioTherapeutics

Discover the tools Aeglea BioTherapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Aeglea BioTherapeutics Email Formats and Examples

Aeglea BioTherapeutics likely uses common corporate email formats. The most probable format combines the first initial and last name, or first name.last name.

[first_initial][last]@aegleabio.com

Format

jgoldberg@aegleabio.com

Example

70%

Success rate

News and media

GlobeNewswireFebruary 13, 2024

Aeglea BioTherapeutics Announces Receipt of Nasdaq Delinquency Notice

Aeglea BioTherapeutics announced it received a delinquency notification letter from Nasdaq due to not timely filing its Quarterly Report on Form 10-Q for the period ended September 30, 2023....more

BioSpaceNovember 14, 2023

Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Aeglea provided an update on its ongoing strategic review process and reported Q3 financial results, highlighting continued efforts to evaluate all options to maximize shareholder value after pegzilarginase trial disappointment....more

GlobeNewswireJune 26, 2023

Aeglea BioTherapeutics Announces Appointment of Jeffrey Goldberg as President and Chief Executive Officer and Provides Corporate Update

Aeglea announced the appointment of Jeffrey Goldberg as President and CEO, succeeding Dr. Anthony Quinn. The company also provided an update on its strategic review following the Phase 3 trial results of pegzilarginase....more

Fierce BiotechMay 1, 2023

Aeglea BioTherapeutics slashes workforce, CEO departs after rare disease drug flops phase 3

Aeglea BioTherapeutics announced a significant workforce reduction and the departure of its CEO Anthony Quinn, M.D., Ph.D., after its lead candidate, pegzilarginase, failed to meet its primary endpoint in a Phase 3 trial for Arginase 1 Deficiency....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Aeglea BioTherapeutics, are just a search away.